231 related articles for article (PubMed ID: 12441717)
1. Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4.
Rubin GS; Bressler NM;
Retina; 2002 Oct; 22(5):536-44. PubMed ID: 12441717
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
[TBL] [Abstract][Full Text] [Related]
3. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
Bressler NM;
Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
[TBL] [Abstract][Full Text] [Related]
5. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
Verteporfin In Photodynamic Therapy Study Group
Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
[TBL] [Abstract][Full Text] [Related]
6. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
[TBL] [Abstract][Full Text] [Related]
7. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
Blumenkranz MS; Bressler NM; Bressler SB; Donati G; Fish GE; Haynes LA; Lewis H; Miller JW; Monés JM; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Schachat AP; Schmidt-Erfurth U; Sickenburg M; Singerman LJ; Slakter JS; Strong A; Vannier S;
Arch Ophthalmol; 2002 Oct; 120(10):1307-14. PubMed ID: 12365909
[TBL] [Abstract][Full Text] [Related]
8. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.
Azab M; Benchaboune M; Blinder KJ; Bressler NM; Bressler SB; Gragoudas ES; Fish GE; Hao Y; Haynes L; Lim JI; Menchini U; Miller JW; Mones J; Potter MJ; Reaves A; Rosenfeld PJ; Strong A; Su XY; Slakter JS; Schmidt-Erfurth U; Sorenson JA; ;
Retina; 2004 Feb; 24(1):1-12. PubMed ID: 15076937
[TBL] [Abstract][Full Text] [Related]
9. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.
Kaiser PK;
Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1132-42. PubMed ID: 16538452
[TBL] [Abstract][Full Text] [Related]
10. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
Blinder KJ; Bradley S; Bressler NM; Bressler SB; Donati G; Hao Y; Ma C; Menchini U; Miller J; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Strong HA; Stur M; Su XY; Virgili G; ;
Am J Ophthalmol; 2003 Sep; 136(3):407-18. PubMed ID: 12967792
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.
Verteporfin in Photodynamic Therapy Study Group
Ophthalmology; 2001 May; 108(5):841-52. PubMed ID: 11320011
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
Miller JW; Schmidt-Erfurth U; Sickenberg M; Pournaras CJ; Laqua H; Barbazetto I; Zografos L; Piguet B; Donati G; Lane AM; Birngruber R; van den Berg H; Strong A; Manjuris U; Gray T; Fsadni M; Bressler NM; Gragoudas ES
Arch Ophthalmol; 1999 Sep; 117(9):1161-73. PubMed ID: 10496388
[TBL] [Abstract][Full Text] [Related]
13. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Japanese Age-Related Macular Degeneration Tial (JAT) Study Group
Am J Ophthalmol; 2003 Dec; 136(6):1049-61. PubMed ID: 14644215
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
Schmidt-Erfurth U; Miller JW; Sickenberg M; Laqua H; Barbazetto I; Gragoudas ES; Zografos L; Piguet B; Pournaras CJ; Donati G; Lane AM; Birngruber R; van den Berg H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
[TBL] [Abstract][Full Text] [Related]
15. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.
Keam SJ; Scott LJ; Curran MP
Drugs; 2003; 63(22):2521-54. PubMed ID: 14609361
[TBL] [Abstract][Full Text] [Related]
16. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
Pieramici DJ; Bressler SB; Koester JM; Bressler NM
Arch Ophthalmol; 2006 May; 124(5):660-4. PubMed ID: 16682587
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.
Saperstein DA; Rosenfeld PJ; Bressler NM; Rosa RH; Sickenberg M; Sternberg P; Aaberg TM; Aaberg TM; Reaves TA;
Ophthalmology; 2002 Aug; 109(8):1499-505. PubMed ID: 12153802
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy in practice: a review of the results of the first 12 months experience with verteporfin at the Royal Victorian Eye and Ear Hospital.
Essex RW; Qureshi SH; Cain MS; Harper CA; Guymer RH
Clin Exp Ophthalmol; 2003 Dec; 31(6):476-81. PubMed ID: 14641153
[TBL] [Abstract][Full Text] [Related]
19. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
[TBL] [Abstract][Full Text] [Related]
20. [Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients].
Chen YX; Ge J; Yan M; Jin CJ; Zhang MX; Dong FT; Lu F; Zhang CF; Zhao JL
Zhonghua Yan Ke Za Zhi; 2007 Mar; 43(3):198-205. PubMed ID: 17605900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
